Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 2 August 2024, including: Pfizer Inc. bullish on its oral GLP-1; Bristol Myers Squibb Company’s rising confidence about Medicare pricing of Eliquis; more long term data for Leqembi; NewAmsterdam Pharma BV’s CETP inhibitor shows promise; and a look at Mankind Pharma Ltd.’s Bharat Serums And Vaccines Limited (BSV) buy.
This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Pfizer Bullish On Danuglipron’s Position In Oral GLP-1 Race" - Scrip, 30 July, 2024.)
(Also see "BMS ‘Increasingly Confident’ It Can Handle The Impact Of Medicare Pricing For Eliquis" - Scrip, 26 July, 2024.)
(Also see "Time Is On Eisai’s Side As More Long-Term Data Emerge For Leqembi" - Scrip, 30 July, 2024.)
(Also see "CETP Gets Another Go: NewAmsterdam Phase III Trial Shows Safety And Efficacy" - Scrip, 29 July, 2024.)
(Also see "$1.6bn Bharat Serums Buy Gives Mankind Dominance In Women's Health, R&D Engine" - Scrip, 29 July, 2024.)
